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Background: A genome-wide association study uncovered Chitinase 3 like 1 (CHI3L1) as a candidate gene for
asthma susceptibility. CHI3L1, which encodes the YKL-40 protein, is associated with asthma in Western European
and American populations and with atopy in a Korean population. However, asthma-associated polymorphisms
remain unknown for a Taiwanese population.
Methods: We enrolled 628 adult asthmatic patients and 1:1 age-sex matched community-based controls in southern
Taiwan and performed a combined effect sizes analysis to test if CHI3L1 polymorphisms were related to genetic risks
for asthma in the Asian population. Ten tagSNP polymorphisms for the CHI3L1 gene were selected from the HapMap
database and genotyped using a TaqMan allelic discrimination assay.
Results: Adjusted odds ratios of the CHI3L1 rs1538372 CC genotype (aOR = 1.97, 95% CI: 1.23–3.14) and the rs10399931
GG genotype (aOR = 1.77, 95% CI: 1.13–2.77) were significantly associated with asthma in the Taiwanese populations.
Predictive values of forced expiratory volume in the first second of the forced vital capacity (12.37%, P = 0.03) and of
forced vital capacity (12.10%, P = 0.036) decreased in conjunction with an increase in YKL-40 levels among CHI3L1
rs1538372 CC carriers; these values were 16.1% (P = 0.004) and 14.5% (P = 0.011), respectively, among CHI3L1
rs10399931 GG carriers. Furthermore, steroid use by asthma patients did not affect serum YKL-40 levels, but both
polymorphisms had significant effects on YKL-40 levels in asthma patients who used steroids.
Conclusions: Our findings suggest that the CHI3L1 polymorphisms rs1538372 and rs10399931 can be used as genetic
markers for predicting asthma risk in the Taiwanese population.
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Asthma has a complicated etiology, including airway in-
flammation, bronchial hyper-responsiveness, and a vari-
able degree of airway obstruction that is influenced by
environmental [1] and genetic factors [2]. This disease
impacts more than 300 million people worldwide and
has detrimental effects on the quality of life [3].
Chitin is a widely abundant polysaccharide in nature,
which triggers allergies or asthma attacks in people. It is
found in fungi, as well as many arthropods, including cock-
roaches, house dust mites, and seafood crustaceans (such
as shrimp, prawn, and crab). The mammalian 18 glycosyl* Correspondence: wangtn@kmu.edu.tw
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unless otherwise stated.hydrolase family has three members, two of which are
chitinase chitotriosidase (CHIT1) and acidic mamma-
lian chitinase (AMCase), with evolutionarily conserved
glycosyl hydrolase activities that cleave chitin and con-
sequently regulate the innate immune response [4].
The third 18 glycosyl hydrolase family member, YKL-
40, is encoded by the chitinase 3-like 1 (CHI3L1) gene
located on chromosome 1q32.1 (also called human cartilage
gp-39/HcGp-39 or breast regression protein 39/BRP-39)
[5,6]. YKL-40 has chitin-binding activity but lacks chitinase
activity and is produced by the airway epithelium, alveolar
macrophages, lung fibroblasts, chondrocytes, synovial cells,
breast cells, and hepatic cells. In addition, YKL-40 plays
critical roles in inflammation, tissue remodeling, and fi-
brosis during infection, joint disease, liver fibrosis, and
cancer [7]. Additionally, novel functions of YKL-40 are. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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fully demonstrated in BRP-39 gene knockout mice and
YKL-40 transgenic mice [8].
Previous cohort studies have shown that elevated
levels of serum YKL-40 are significantly associated with
asthmatic severity and poor lung function, because the
thickness of the bronchial subepithelial basement
membrane is positively correlated with YKL-40 levels
[9]. A genome-wide association study of asthma indi-
cated that the single nucleotide polymorphism (SNP)
rs4950928 in the promoter region of CHI3L1 is asso-
ciated with serum levels of YKL-40 in Western Euro-
pean and American populations [10,11], and another
study illustrated that the rs4950928 G allele is signi-
ficantly associated with asthma susceptibility in a
population-based study of 6514 Danish adults [12].
Moreover, rs10399805 and rs2275353 in CHI3L1 were
found be significantly associated with atopy but not
asthma in a Korean population [13].
Although another study in sixty-two asthmatic pa-
tients found YKL-40 levels correlated with exacerbation
of attacks [14], whether inherent and susceptible genetic
variance of CHI3L1 affects the serum YKL-40 protein
levels that cause asthmatic severity in a Taiwanese popu-
lation is not known. Therefore, we selected 10 tagSNPs
of the CHI3L1 gene using Tagger pairwise methods, ex-
plored the association between the CHI3L1 gene and
asthma risk, and measured decreased lung function with
forced expiratory volume in the first second of the
forced vital capacity (FEV1) and forced vital capacity




We enrolled adult asthmatic patients and 1:1 age-sex
matched community-based controls in southern Taiwan.
The asthmatic patients were diagnosed at Kaohsiung
Chang Gung Memorial Hospital (CGMH) and Kao-
hsiung Medical University Hospital (KMUH). The 628
adult asthmatic patients had symptoms such as cough,
wheezing, episodic breathlessness, and chest tightness
according to the Global Initiative for Asthma guidelines
and/or an increase in FEV1 of ≥12% and at least 200 mL
from the prebronchodilator value based on lung func-
tion testing [15]. The 628 healthy control subjects were
recruited at local health stations in the same geographic
communities as our previous description [16]. In the
study, all subjects with symptoms indicating lung cancer,
tuberculosis, bronchitis, or pneumonia were excluded.
All participants provided informed written consent,
which was reviewed and approved by the Institutional
Review Boards of CGMH and KMUH (ethics approval
numbers, CGMH-101-0614C and KMUH-IRB-980553).Ascertainment of relevant metrics
Blood samples were collected from all participants who
completed a questionnaire that collected comprehensive
information regarding demographics, smoking habits,
parents’ asthmatic history, history of atopic disease diag-
nosed by a physician, steroid use (including oral or inhaled
steroids), and environmental exposure factors. Spirometry
was performed according to the American Thoracic
Society standards [17], and FEV1and FVC were mea-
sured. All recorded data were measured three times,
and the highest score was recorded under stable conditions.
Total blood serum immunoglobulin E (IgE) and YKL-40
protein levels were measured using a microparticle enzyme
immunoassay (IMX system Abbot, Tokyo, Japan) and the
DuoSet® ELISA Development System (R&D Systems, Inc.,
Minneapolis, MN, USA), respectively.
TagSNP selection and genotyping
The CHI3L1 tagSNPs (rs903358, rs7542294, rs946259,
rs880633, rs12128727, rs1538372, rs10399805, rs10399931,
rs6691378, and rs946261) were selected by using the
Tagger pairwise and linkage disequilibrium (LD) mea-
surement methods on the HapMap2009 NCBI B36
assembly Chinese Han (CHB) database with minor
allele frequency (MAF) ≥0.05 and r2 ≥ 0.80. Linkage
disequilibrium blocks of the CHI3L1 gene region ex-
tending from 201,413 kb to 201,430 kb on chromo-
some 1 were established in Haploview version 4.2
(http://www.broadinstitute.org) (Figure S1 in the on-
line Additional file 1). Overall, the characteristics of
the 10 tagSNPs are described in Table S1 in the online
Additional file 2. Genomic DNA was isolated from
peripheral blood using the Purgene DNA Isolation
Kit (Gentra Systems, Inc., Minneapolis, MN, USA).
Genotyping was performed with the TaqMan® SNP
Genotyping Assay standard protocol with a 7900HT
Fast Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA). Duplicate genotyping of 10%
of the samples (selected randomly) was performed for
quality control.
Statistical analysis
All analyses were performed using IBM SPSS Statistics
release 19.0 (SPSS Inc., an IBM Company, Chicago, IL,
USA). Comparisons of the asthmatic and control sub-
jects were conducted using Pearson’s chi-squared test
for the dichotomous variables and the t test for the
continuous variables. Serum IgE and YKL-40 levels did
not show a normal distribution on the Shapiro–Wilk
test (P < 0.001) and needed to be log-transformed
for normality. We performed using the Pearson’s
chi-squared test to assess Hardy–Weinberg equilib-
rium for allele distribution in the asthmatic and con-
trol groups. Adjusted odds ratios (aORs) with 95%
Tsai et al. BMC Medical Genetics 2014, 15:86 Page 3 of 8
http://www.biomedcentral.com/1471-2350/15/86confidence intervals (CI) according to carriers of reces-
sive, dominant, and co-dominant genotypes were
assessed with logistic regression analysis adjusting for
sex, age, body mass index (BMI), log IgE, smoking, ex-
posure to pets, indoor incense burning, and parental
asthma history. To examine the effects of CHI3L1
genotype on quantitative clinical characteristics in
asthmatic patients and controls groups, we performedTable 1 The demographic characteristics of asthmatics and co
Asthma Na = 628




Height (cm)b 162.15 ± 8.33
Weight (kg)b 66.56 ± 12.47
BMI (kg/m2)ab 25.27 ± 4.07
WC (cm)ab 86.93 ± 11.18
Hips (cm)b 99.33 ± 8.88
WHRab 0.88 ± 0.08
IgE (IU/mL)b 262.04 ± 584.65
YKL-40 (ng/mL)b 112.84 ± 111.56
Lung functionb
FEV1%, pred 81.75 ± 21.53
FVC%, pred 85.75 ± 21.31










Pets (dogs, cats, birds) 190 (30.4%)
Appearance of cockroaches 491 (%)
Air cleaner 102 (16.3%)
Dehumidifiers 140 (22.5%)
Carpet 26 (4.2%)
Mold in walls 108(17.3%)
Indoor incense burning 402 (64.5%)
Asthma history for father, yes 69 (11.2%)
Asthma history for mother, yes 51 (8.2%)
aAbbreviations: BMI body mass index, WC waist circumference, WHR waist-to-hips ra
bValues are expressed as the means ± standard deviation (SD) unless otherwise stat
cThe P value of the IgE and YKL-40 serum levels was determined by t test after log-
dThe P value was calculated for the continuous variables by the t test, and the χ2 teANOVA with a Bonferroni adjustment (post hoc com-
parison) and multiple linear regressions adjusting for
age, sex, log IgE, BMI, and smoking as covariates.
Results
Characteristics of patients
Between the 628 asthmatic patients and 628 healthy
controls, there were significant differences in bodyntrols
Control Na = 628 P valued
50.42 ± 11.84 0.522
289 (46.0%) 1.000
339 (54.0%)
161.82 ± 8.28 0.481
63.04 ± 11.86 <0.001
23.95 ± 3.40 <0.001
78.58 ± 9.51 <0.001
95.74 ± 6.62 <0.001
0.82 ± 0.08 <0.001
128.07 ± 291.48 <0.001c
95.65 ± 101.46 0.005c
92.17 ± 16.41 <0.001
97.36 ± 17.05 <0.001
















tio, N number of individuals.
ed.
transformation.
st was used for the categorical variable.
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to-hip ratio, serum IgE and YKL-40 levels, lung function,
smoking and drinking behavior, exposure to indoor pets
and incense burning, and parents’ asthma history (Table 1).
CHI3L1 tagSNP association study
For the association analysis, we identified 10 tagSNPs for
CHI3L1 from the HapMap 2009 NCBI B36 assembly of
the Chinese Han database (Table S1 in Additional file 2).
The association results are presented in Table S2 in
Additional file 3. CHI3L1 genotypes and allele carrier
frequencies were calculated in the asthmatic patients
and controls.
No deviation from Hardy–Weinberg equilibrium was
observed for the 10 tagSNPs. Only rs1538372 (P = 0.014)
and rs10399931 (P = 0.047) had a nominally significant
association with asthma, respectively. However, the
two polymorphisms rs1538372 (P = 0.14) and rs10399931
(P = 0.47) and other eight genotypes were not significantly
associated with asthma after applying the Bonferroni
correction.
Furthermore, we observed that for the aOR in rs1538372,
the CC genotype was associated with an increased risk ofTable 2 The adjusted odd ratios between asthma status and























GA + GG 556/536
aAdjusted odds ratio and 95% confidence intervals (aOR and 95% CI) are shown usi
logIgE, smoking, pet exposure, indoor incense burning, and parents’ asthma historyasthma compared with the TT genotype (aOR = 1.97, 95%
CI 1.23–3.14). For rs10399931, the GG genotype was asso-
ciated with an increased risk of asthma compared with the
AA genotype (aOR = 1.77, 95% CI 1.13–2.77) (Table 2).
Association of clinical quantitative characteristics
We investigated the differences in clinical quantitative
traits, including adiposity, serum levels of IgE and YKL-40,
and lung function, among subjects with CHI3L1 rs1538372
and rs10399931 genotypes in asthmatic patients and
control groups. A significant association was revealed
between the rs1538372 and rs10399931 genotypes and
serum YKL-40 protein levels (Table 3). In this study,
we found that FEV1% and FVC% decreased by 12.37%
(P = 0.03) and 12.10% (P = 0.036), respectively, as YKL-
40 levels were higher in CHI3L1 rs1538372 CC carriers
than in TC or TT carriers. Similarly, FEV1% and FVC%
in subjects with CHI3L1 rs10399931 GG genotype
were significantly lower at -16.1% (P = 0.004) and -14.5%
(P = 0.011), respectively (Table 4).
Further, using CHI3L1 polymorphisms, we determined
whether steroid use affected serum YKL-40 levels in
asthmatics. We found no significant difference in serumthe CHI3L1 polymorphisms rs1538372 and rs10399931
OR (95% CI) aOR (95% CI)a
1 1
1.3 (0.91–1.86) 1.54 (0.98–2.43)
1.65 (1.15–2.38) 1.97 (1.23–3.14)
1 1
1.34 (1.07–1.68) 1.39 (1.04–1.86)
1 1
1.45 (1.03–2.04) 1.72 (1.11–2.66)
1 1
1.16 (0.82–1.65) 1.36 (0.88–2.10)
1.47 (1.03–2.11) 1.77 (1.13–2.77)
1 1
1.31 (1.04–1.64) 1.39 (1.04–1.86)
1 1
1.30 (0.93–1.81) 1.53 (1.01–2.32)
ng multiple logistic regressions to control variables, including sex, age, BMI,
.
Table 3 The associations of the CHI3L1 rs1538372 and rs10399931 polymorphisms with clinical status and
characteristics in asthma and control groups
Asthma Control
rs1538372 CC (N = 270) CT (N = 293) TT (N = 65) P value CC (N = 226) CT (N = 311) TT (N = 91) P value
Age (year) 51.40 ± 14.26 51.14 ± 14.08 52.91 ± 13.91 0.66 50.00 ± 11.86 50.78 ± 11.64 50.22 ± 12.58 0.743
Sex
Male 120 (44.4%) 142 (48.5%) 27 (41.5%) 0.472 108 (47.8%) 141 (45.3%) 40 (44.0%) 0.779
Female 150 (55.6%) 151(51.5%) 38 (58.5%) 118 (52.2%) 170 (54.7%) 51 (56.0%)
BMI (kg/m2) 25.31 ± 4.25 25.3 ± 3.93 25.00 ± 3.92 0.846 23.85 ± 3.54 23.88 ± 3.31 24.47 ± 3.36 0.332
WC (cm) 86.70 ± 12.00 87.18 ± 10.83 86.74 ± 8.89 0.888 79.21 ± 10.20 77.67 ± 9.03 80.06 ± 9.02 0.113
WHR 0.88 ± 0.09 0.88 ± 0.08 0.87 ± 0.06 0.764 0.83 ± 0.10 0.81 ± 0.07 0.82 ± 0.07 0.041
IgE (IU/mL) 279.24 ± 648.79 221.09 ± 399.22 375.48 ± 913.44 0.7a 111.64 ± 190.17 137.02 ± 337.76 140.32 ± 336.82 0.619a
YKL-40 (ng/mL) 130.00 ± 126.89 103.79 ± 101.13 81.18 ± 69.18 < 0.0001a 115.47 ± 128.54 88.441 ± 84.23 68.32 ± 61.35 0.011a
FEV1%, pred 84.00 ± 20.66 79.71 ± 21.73 79.26 ± 23.42 0.046 91.91 ± 17.46 93.36 ± 15.64 88.75 ± 15.88 0.16
FVC%, pred 87.47 ± 21.03 84.32 ± 20.40 84.94 ± 25.67 0.216 97.08 ± 16.90 97.52 ± 17.78 97.54 ± 15.01 0.97
rs10399931 GG (N = 270) GA (N = 286) AA (N = 72) P value GG (N = 229) GA (N = 307) AA (N = 90) P value
Age (year) 51.28 ± 14.14 51.16 ± 14.06 53.13 ± 14.41 0.557 50.32 ± 11.63 50.32 ± 11.79 50.97 ± 12.72 0.892
Sex
Male 122 (45.2%) 136 (47.6%) 31 (43.1%) 0.741 112 (48.9%) 136 (44.3%) 40 (44.4%) 0.542
Female 148 (54.8%) 150 (52.4%) 41 (56.9%) 117 (51.1%) 171 (55.7%) 50 (55.6%)
BMI (kg/m2) 25.24 ± 4.29 25.36 ± 3.87 25.06 ± 4.04 0.843 23.82 ± 3.33 23.96 ± 3.46 24.16 ± 3.34 0.723
WC (cm) 86.54 ± 11.91 87.08 ± 10.87 87.78 ± 9.47 0.712 78.84 ± 9.71 78.08 ± 9.50 79.40 ± 9.01 0.534
WHR 0.87 ± 0.09 0.88 ± 0.08 0.88 ± 0.07 0.942 0.83 ± 0.10 0.82 ± 0.07 0.82 ± 0.07 0.399
IgE (IU/mL) 276.80 ± 645.41 229.82 ± 454.97 331.63 ± 768.03 0.613 95.65 ± 155.72 150.11 ± 346.92 139.44 ± 351.86 0.511
YKL-40 (ng/mL) 133.08 ± 128.56 99.16 ± 89.75 90.66 ± 109.85 < 0.0001a 105.15 ± 103.82 98.89 ± 108.91 63.403 ± 57.64 0.009a
FEV1%, pred 83.20 ± 20.89 80.96 ± 22.16 77.41 ± 21.05 0.116 92.81 ± 18.37 92.91 ± 14.58 88.30 ± 16.71 0.127
FVC%, pred 86.79 ± 20.83 85.09 ± 21.67 84.44 ± 21.79 0.562 98.69 ± 18.26 96.42 ± 16.31 97.18 ± 16.48 0.463
aP value was presented by testing the total serum IgE and YKL-40 levels after log-transformation to follow normal distribution. (ANOVA and Bonferroni).
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did not use steroids (Figure 1A). However, it is note-
worthy that YKL-40 levels varied by rs1538372 genotypes
(CC >TC >TT, P for trend = 0.001) and rs10399931 (GG >
GA>AA, p for trend = 0.001) in asthmatic patients who
used steroids (Figure 1B).Table 4 The correlations between serum YKL-40 levels and lu
asthmatics
Lung function FEV1% pred
Serum YKL40 level (log-transformation) β ± SE r coeffi
rs1538372
TT −3.61 ± 11.768 −0.049
TC −11.38 ± 5.20 −0.151
CC −12.37 ± 5.526 −0.158
rs10399931
AA −12.11 ± 8.644 −0.202
GA −6.90 ± 5.83 −0.083
GG −16.10 ± 5.50 −0.205
aLinear regression was performed adjusting for age, sex, logIgE, BMI, and smoking.Discussion
Following the discovery that CHI3L1 variation affects
serum YKL-40 levels, the risk of asthma and impaired lung
function were studied in Western European and American
populations with a genome-wide association method [10].
In fact, we are the first to demonstrate that the CHI3L1ng functions according to the CHI3L1 polymorphisms in
icted Lung function FVC% predicted
cient P valuea β ± SE r coefficient P valuea
0.761 0.379 ± 13.74 0.004 0.978
0.03 −12.95 ± 5.01 −0.177 0.01
0.026 −12.10 ± 5.71 −0.149 0.036
0.168 −11.60 ± 9.95 −0.17 0.249
0.238 −8.98 ± 5.74 −0.11 0.119
0.004 −14.5 ± 5.70 −0.18 0.011
Figure 1 The YKL-40 levels were affected by rs1538372 and rs10399931 genotypes in asthmatics. (A) The serum YKL-40 levels were
assessed in asthmatics using steroids or not using steroids. Mean ± standard error (SE) is shown with significance assessed by t test. (B) The serum
YKL-40 levels were analyzed according to rs1538372 and rs10399931 genotypes in asthmatics using steroids or not using steroids. Mean ± standard
error (SE) is shown. The mean trend tests were performed by entering cross-categorized variables as a continuous variable into the linear regression
model and including multiple testing corrections (Bonferroni; P* < 0.05).
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population were not only significantly associated with asthma
risk, but also related to serum YKL-40 concentrations with a
gene-dose dependent relationship. At the same time, we
found that the percent predictive value of FEV1 and FVC
among CHI3L1 rs1538372 CC carriers was lower than in TC
or TT carriers, and similar findings were observed for
rs10399931 GG carriers compared to GA or AA carriers.
In a Korean population study (198 asthmatics and 277
non-asthmatics), the C versus T allele of the rs1538372
polymorphism and the G versus A allele of rs10399931
polymorphism were associated with an increased risk ofasthma (OR = 1.26 and 1.19, respectively) [13]. However,
the differences were not statistically significant; therefore, it
was concluded that the two polymorphisms did not in-
crease asthma risk. Interestingly, our matched data set (628
asthmatics and 628 controls) gave significant odds ratios
for the rs1538372 C allele (OR = 1.27, 95% CI: 1.08-1.49)
and the rs10399931 G allele (OR = 1.22, 95% CI: 1.04-1.44)
associations with asthma. The differences between the
studies are due to the different sample sizes. Overall, the
two SNPs were consistently associated with increased
asthma risk and could be considered important risk
markers for asthma in Asians.
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reporter vectors including three variant genotypes: the
rs10399931 C allele (complementary to the G risk allele
on the reverse strand), the rs10399805 A allele, and the
rs4950928 C allele. Their study found that the haplotype
CAC (or GTG haplotype) has the highest promoter acti-
vity compared with the other haplotypes. They concluded
that rs103999331 and rs4950925 are equally likely to
modulate CHI3L1 expression and susceptibility to asthma
in Caucasian and African populations.
To treat asthmatic patients in the clinical setting, in-
haled or oral glucocorticoids are commonly administered,
owing to their direct inhibitory effects on airway inflam-
mation [19]. Glucocorticoid is a type of steroid hormone
that binds to the glucocorticoid receptor to translocate
into the nucleus, where it binds to specific DNA elements
to regulate gene expression [20]. We found that the tran-
scription factor–binding sites of glucocorticoid receptor
element (GRE) and STAT1 are closer to rs1538372 and
that cAMP response element–binding protein (CREBP1)
and E4 promoter–binding protein 4 (E4BP4) are closer to
rs10399931 from UCSC Genome Browser (NCBI36/hg18)
[21,22] (Figure S2 in the online Additional file 4 and Table
S3 in the online Additional file 5). There is convincing evi-
dence for STAT1 constitutive activation in the asthmatic
airway epithelium [23]. The E4BP4 protein, which binds
to elements located on the promoters of the repressed
COX-2 and iNOS genes, was induced by glucocorticoid
dexamethasone [24]. Thus, the two SNPs in the CHI3L1
gene might be affected by glucocorticoids.
Here, we first found that serum YLK-40 levels were
not different between asthmatic patients who did or did
not use steroids. Furthermore, serum YKL-40 levels were
highly elevated by dependent genotypes in steroid-using
asthma patients with rs1538372 CC and rs10399931
GG. These results showed that the rs1538372 CC and
rs10399931 GG are risk genotypes associated with se-
verity of asthmatic lung function. The steroid-using
asthmatic subjects who have genotypes rs1538372 CC
and rs10399931 GG will be examined in a future study
to clarify whether these risk carriers might be associ-
ated with steroid resistance.
Here, we summarized the mechanisms of regulation of
CHI3L1 gene expression on bronchial epithelium, smooth
muscle, monocytes, and macrophages to elucidate the role
of the CHI3L1 gene in asthmatic pathology. We factored in
numerous environmental factors, such as smoking, house
dust mite exposure [25], rhinovirus [26], lipopolysaccharide
infection [27], and interleukin 13 [8]. It is well known that
the AKT-MAPK-ATF2 or STAT1 signaling pathways are
implicated in YKL-40 expression or exacerbation of asthma
symptoms (Figure S3 in the online Additional file 6).
Overall, the limitations of the study need to be discussed.
We found that the CHI3L1 polymorphisms rs1538372 andrs10399931 had an r2 of 0.84 in a linkage disequilibrium
plot (Additional file 2: Table S1) and a nominally significant
association with asthma (P < 0.05). The correlations were
not significant after Bonferroni correction. However, two
SNPs were significantly associated with asthma and signifi-
cantly associated with serum YKL-40 levels and lung func-
tions in asthmatic according to multiple regression models
after adjusting for potential confounding factors. Import-
antly, we managed to reduce false positive results and avoid
excluding small effects through the overly conservative
Bonferroni correction. Furthermore, there are still limita-
tions that require further large-scale exploration to clarify
gene-gene and gene-environment interactions.
Taken together, protein YKL-40 levels are elevated in
many kinds of diseases, such as asthma, multiple sclerosis,
rheumatoid arthritis, osteoarthritis, infectious diseases, car-
diovascular disease, and cancer. Thus, serum YKL-40 levels
are not a specific diagnosis for one disease, and now
several studies question whether unregulated YKL-40 is a
good diagnostic biomarker in many diseases. YKL-40
may not be a good biomarker, but it can reflect poor
prognosis [7] and overall mortality risk [28].
Conclusion
Our findings suggest that CHI3L1 polymorphisms
rs1538372 and rs10399931 can be used as genetic markers
predicting asthma risk in the Taiwanese population.
Additional files
Additional file 1: Figure S1. Linkage disequilibrium plot based on the
HapMap CHB database. The number in each square represents the
standard color scheme (r2) between each pair of SNPs. Ten SNPs
(rs903358, rs7542294, rs946259, rs880633, rs12128727, rs1538372,
rs10399805, rs10399931, rs6691378, and rs946261) are shown.
Additional file 2: Table S1. The ten Tag SNPs of the CHI3L1 primers for
TaqMan PCR in this study.
Additional file 3: Table S2. The associations between asthma and ten
CHI3L1 tag SNPs.
Additional file 4: Figure S2. Box1 (CREBP1 and E4BP4 with rs4950928 and
rs10399931) and Box2 (GRE and STAT1 with rs1538372) show the conserved
transcription factor binding sites (■) and the positions corresponding to the
single nucleotide polymorphism (I) in different ethnic groups, predicted on
chromosome 1 and positioned from 201,420,794 to 201,422,994 (total 2201
bp) by the UCSC Genome Browser (NCBI36/hg18) assembly.
Additional file 5: Table S3. The features of the transcription factor
binding sites in the CHI3L1 promoter region.
Additional file 6: Figure S3. The mechanisms of regulation of CHI3L1
gene expression on bronchial epithelium, smooth muscle, monocytes, and
macrophages by environmental factors. The solid line indicates that the
mechanisms have direct interactions from the journal articles (# References
number) and the dotted line indicates proposed but unverified pathways.
ATF2, activating transcription factor 2; PI3K, phosphoinositide-3-kinase; AKT,
serine–threonine protein kinase. ERK, extracellular signal-regulated kinase;
IL13, interleukin 13; IFN-γ, interferon gamma; LPS, lipopolysaccharide.
C/EBP-alpha, CCAAT/Enhancer Binding Protein, Alpha.
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